Head-to-head Comparison of Empagliflozin and Dapagliflozin

Sponsor
Chungbuk National University Hospital
Study ID
NCT03748810
Status
Completed

Conditions

  • Type2 Diabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin — DRUG
    Empagliflozin 25 mg once daily add on the background OADs for 3 years
  • Dapagliflozin — DRUG
    Dapagliflozin 25 mg once daily add on the background OADs for 3 years

Study Details

This open-labeled, prospective, observational, 3-year, clinical study was conducted to compare the effectiveness and safety between empagliflozin (25 mg once daily) and dapagliflozin (10 mg once daily) in patients with inadequately controlled type 2 diabetes despite preexisting triple OAD combination.

Key Dates

Start date
Jan 1, 2016
Status verified
Jul 2022
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022

Study Design

Enrollment
600 participants (actual)

Arms

  • Arm: Triple OADs failure
    Empagliflozin or dapagliflozin as an add-on drug for inadequately controlled T2D patients who are already receiving a regimen of three distinct OADs, including metformin, glimepiride and dipeptidyl peptidase 4 (DPP4) inhibitors.

Primary Outcome Measure

Changes in HbA1c from baseline to week 156 (3-year) [ Time Frame: Baseline, week 156 (3-year) ]

Related Studies